CYTX Cytori Therapeutics Inc.

0.31
-0.01  -3%
Previous Close 0.31
Open 0.32
Price To Book 0.96
Market Cap 4995791
Shares 16,326,116
Volume 274,175
Short Ratio
Av. Daily Volume 768,479

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released June 24, 2017 - endpoints not met.
ECCS-50
Scleroderma
Phase 2 planned.
ATI-1123
Solid Tumors
Pivotal data due 2Q 2019.
ADRESU
Urinary incontinence

Latest News

  1. Edited Transcript of CYTX earnings conference call or presentation 1-Apr-19 12:30pm GMT
  2. Analysts Expect Breakeven For Cytori Therapeutics, Inc. (NASDAQ:CYTX)
  3. Cytori: 4Q Earnings Snapshot
  4. Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results
  5. Cytori to Webcast Fourth Quarter and 2018 Financial Results on April 1
  6. Cytori Files Pre-submission Request for New Drug Application
  7. Cytori Cell Therapy™ Clinical Trial Results in Crohn’s Disease
  8. Does Cytori Therapeutics, Inc. (NASDAQ:CYTX) Have A High Beta?
  9. Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT
  10. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  11. Shares Of Penny Stock Cytori Rise On Japanese Device Approval
  12. Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
  13. Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates
  14. Cytori Reports Q3 2018 Business and Financial Results
  15. Cytori to Webcast Third Quarter Financial Results on November 14
  16. Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone
  17. Cytori Therapeutics Inc (NASDAQ:CYTX) Is Expected To Breakeven
  18. Cytori's Chemotherapy Candidate Gets Orphan Drug Status